Halozyme Therapeutics HALO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Bulk rHuPH20 sales | $179.5M+74.5% | $133.02M+54.1% | $102.48M+6.9% | $101.49M+0.1% | $102.85M-1.0% | |
| Device licensing and development revenue | $19.05M+58.2% | $16.86M+48.6% | $14.7M+27.8% | $14.07M+38.3% | $12.05M+14.4% | |
| Device partnered product sales | $49.19M-6.1% | $48.81M-3.4% | $48.32M-2.3% | $54.07M+3.4% | $52.4M-7.5% | |
| Proprietary product sales | $200.14M+19.3% | $194.61M+16.8% | $182.34M+15.1% | $170.02M+13.4% | $167.71M+21.4% | |
| Royalties | $940.33M+52.0% | $867.84M+52.0% | $780.29M+49.3% | $699.31M+45.1% | $618.59M+31.9% | |
| Sales-based milestones | $55M+22.2% | $70M+133% | $75M— | $55M— | $45M— | |
| Upfront license and target nomination fees | $18.25M-33.0% | $18.47M-31.6% | $220K-99.2% | $27.22M+1,261% | $27.22M+1,261% | |
| Accounts receivable, net and contract assets by Product | ||||||
| Device partnered product sales | $246.42M+58.7% | $192.06M+46.8% | $159.82M+5.2% | $157.13M-4.8% | $155.29M-7.4% | |
| Royalties | $993.51M+58.7% | $878.98M+57.5% | $784.03M+53.2% | $701.16M+47.5% | $626.1M+35.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Halozyme Therapeutics break its business down?
- Halozyme Therapeutics (HALO) reports revenue from contract with customer, excluding assessed tax by product across 7 parts — Bulk rHuPH20 sales, Device licensing and development revenue, Device partnered product sales, Proprietary product sales and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Halozyme Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Halozyme Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
